VANCOUVER, British Columbia, Oct. 26, 2022 (GLOBE NEWSWIRE) — Voyageur Pharmaceuticals (TSXV:VM) (OTCPink:VYYRF) has signed…
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
BOTHELL, Wash., Oct. 26, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the…
BURLINGTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company…
A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected…
WILLOWBROOK, Ill., Oct. 26, 2022 (GLOBE NEWSWIRE) — Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused…
– Study met safety, tolerability, and pharmacokinetics primary endpoints – – Reductions in ALT, ProC3,…
Topline data, including safety and viral load reduction results from all three cohorts anticipated in…
BDTX-1535 is an irreversible MasterKey inhibitor of multiple EGFR alterations that utilize similar activated oncogenic…
Goal of evaluating combination of novel viral immunotherapies with aim to potentiate CAR-T cell therapies…
FREMONT, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”)…
COPENHAGEN, Denmark, Oct. 26, 2022 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) announced today…
Media Release SYDNEY, AUSTRALIA, Oct. 26, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ:…
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced…
WARMINSTER, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage…
BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted…
POMPANO BEACH, FLORIDA., Oct. 26, 2022 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (“BioStem” or the…
VANCOUVER, British Columbia, Oct. 26, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the…
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent…
Poster for presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics enhances…